Description

This research service covers the United States glaucoma pharmaceuticals market from 2008 to 2016, with 2010 as the base year. Included in the study are products on the market and products in development as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. The market is segmented by classes of drug: prostaglandins, beta-blockers, alpha-adrenerigic agonists, carbonic anhydrase inhibitors, and fixed-dose combinations.